Evidence map›Paper›PMID 32824472›Full record

ReviewInternational journal of molecular sciences2020

Therapeutic Drug Monitoring Is a Feasible Tool to Personalize Drug Administration in Neonates Using New Techniques: An Overview on the Pharmacokinetics and Pharmacodynamics in Neonatal Age.

Domenico Umberto De Rose, Sara Cairoli, Marco Dionisi, Alessandra Santisi, Luca Massenzi, Bianca Maria Goffredo, Carlo Dionisi-Vici, Andrea Dotta, Cinzia Auriti

Open access · goldAbstract readReview
In one paragraph

Review in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 1 pooled it
4.6field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.

  1. Guideline
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Use of Antibiotics in Preterm Newborns.Antibiotics (Basel, Switzerland) · 2022
    Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Domenico Umberto De RoseNeonatal Intensive Care Unit, Department of Medical and Surgical Neonatology, "Bambino Gesù" Children's Hospital IRCCS, 00165 Rome, Italy.ORCID 0000-0002-9076-9838
Sara CairoliLaboratory of Metabolic Biochemistry Unit, Department of Specialist Pediatrics, "Bambino Gesù" Children's Hospital IRCCS, 00165 Rome, Italy.ORCID 0000-0002-5925-0974
Marco DionisiLaboratory of Metabolic Biochemistry Unit, Department of Specialist Pediatrics, "Bambino Gesù" Children's Hospital IRCCS, 00165 Rome, Italy.
Alessandra SantisiNeonatal Intensive Care Unit, Department of Medical and Surgical Neonatology, "Bambino Gesù" Children's Hospital IRCCS, 00165 Rome, Italy.
Luca MassenziNeonatal Intensive Care Unit and Neonatal Pathology, Fatebenefratelli Hospital, 00186 Rome, Italy.ORCID 0000-0002-4831-3570
Bianca Maria GoffredoLaboratory of Metabolic Biochemistry Unit, Department of Specialist Pediatrics, "Bambino Gesù" Children's Hospital IRCCS, 00165 Rome, Italy.
Carlo Dionisi-ViciLaboratory of Metabolic Biochemistry Unit, Department of Specialist Pediatrics, "Bambino Gesù" Children's Hospital IRCCS, 00165 Rome, Italy.ORCID 0000-0002-0007-3379
Andrea DottaNeonatal Intensive Care Unit, Department of Medical and Surgical Neonatology, "Bambino Gesù" Children's Hospital IRCCS, 00165 Rome, Italy.ORCID 0000-0002-1260-6427
Cinzia AuritiNeonatal Intensive Care Unit, Department of Medical and Surgical Neonatology, "Bambino Gesù" Children's Hospital IRCCS, 00165 Rome, Italy.
Bambino Gesù Children's Hospital · ITFatebenefratelli Hospital · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Therapeutic drug monitoring (TDM) should be adopted in all neonatal intensive care units (NICUs), where the most preterm and fragile babies are hospitalized and treated with many drugs, considering that organs and metabolic pathways undergo deep and progressive maturation processes after birth. Different developmental changes are involved in interindividual variability in response to drugs. A crucial point of TDM is the choice of the bioanalytical method and of the sample to use. TDM in neonates is primarily used for antibiotics, antifungals, and antiepileptic drugs in clinical practice. TDM appears to be particularly promising in specific populations: neonates who undergo therapeutic hypothermia or extracorporeal life support, preterm infants, infants who need a tailored dose of anticancer drugs. This review provides an overview of the latest advances in this field, showing options for a personalized therapy in newborns and infants.

Indexed as

AnticonvulsantsAnti-Infective AgentsDrug Elimination RoutesDrug MonitoringHumansInfant, NewbornMetabolic Clearance RatePrecision MedicineAnticonvulsantsAnti-Infective Agentsdrugsinfantsneonatesnewbornspersonalized medicinepharmacodynamicspharmacokineticstherapeutic drug monitoring

Identifiers

PMID32824472
PMCPMC7460644
OpenAlexW3049395809

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.